Stop Alzheimerâ€₅™before it starts

Nature 547, 153-155 DOI: 10.1038/547153a

Citation Report

#	Article	IF	CITATIONS
1	Anti-Aβ single-chain variable fragment antibodies restore memory acquisition in a Drosophila model of Alzheimer's disease. Scientific Reports, 2017, 7, 11268.	3.3	13
2	β-Amyloid and the Pathomechanisms of Alzheimer's Disease: A Comprehensive View. Molecules, 2017, 22, 1692.	3.8	82
3	BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer's Disease Pathology. Molecules, 2017, 22, 1723.	3.8	89
4	Effect of solvent selectivity on crystallization-driven fibril growth kinetics of diblock copolymers. Polymer, 2018, 138, 359-362.	3.8	23
5	A solution NMR toolset to probe the molecular mechanisms of amyloid inhibitors. Chemical Communications, 2018, 54, 4644-4652.	4.1	33
6	Next generation antibody drugs: pursuit of the 'high-hanging fruit'. Nature Reviews Drug Discovery, 2018, 17, 197-223.	46.4	595
7	Precision pharmacology for Alzheimer's disease. Pharmacological Research, 2018, 130, 331-365.	7.1	79
8	Human Neurospheroid Arrays for In Vitro Studies of Alzheimer's Disease. Scientific Reports, 2018, 8, 2450.	3.3	98
9	A roadmap towards personalized immunology. Npj Systems Biology and Applications, 2018, 4, 9.	3.0	43
10	Discovery of Selective, Substrate-Competitive, and Passive Membrane Permeable Glycogen Synthase Kinase-3l² Inhibitors: Synthesis, Biological Evaluation, and Molecular Modeling of New <i>C</i> -Glycosylflavones. ACS Chemical Neuroscience, 2018, 9, 1166-1183.	3.5	32
11	Interaction between Ester-Type Tea Catechins and Neutrophil Gelatinase-Associated Lipocalin: Inhibitory Mechanism. Journal of Agricultural and Food Chemistry, 2018, 66, 1147-1156.	5.2	23
12	Amyloid-Beta Solubility in the Treatment of Alzheimer's Disease. New England Journal of Medicine, 2018, 378, 391-392.	27.0	39
13	NMR-driven identification of anti-amyloidogenic compounds in green and roasted coffee extracts. Food Chemistry, 2018, 252, 171-180.	8.2	47
14	The physics of polymer chain-folding. Physics Reports, 2018, 747, 1-50.	25.6	126
15	A sensitive detection assay based on signal amplification technology for Alzheimer's disease's early biomarker in exosome. Analytica Chimica Acta, 2018, 1022, 124-130.	5.4	38
16	Behavioral and psychological symptoms of dementia (BPSD) and impaired cognition reflect unsuccessful neuronal compensation in the pre-plaque stage and serve as early markers for Alzheimer's disease in the APP23 mouse model. Behavioural Brain Research, 2018, 347, 300-313.	2.2	20
17	Traced on the Timeline: Discovery of Acetylcholine and the Components of the Human Cholinergic System in a Primitive Unicellular Eukaryote <i>Acanthamoeba</i> spp ACS Chemical Neuroscience, 2018, 9, 494-504.	3.5	18
18	Amyloid-β and tau complexity — towards improved biomarkers and targeted therapies. Nature Reviews Neurology, 2018, 14, 22-39.	10.1	303

#	Article	IF	CITATIONS
19	Fluid biomarker agreement and interrelation in dementia due to Alzheimer's disease. Journal of Neural Transmission, 2018, 125, 193-201.	2.8	5
20	Genetics of Parkinson's disease and related disorders. Journal of Medical Genetics, 2018, 55, 73-80.	3.2	55
21	The Ethyl Acetate Extract of Leaves of Ugni molinae Turcz. Improves Neuropathological Hallmarks of Alzheimer's Disease in Female APPswe/PS1dE9 Mice Fed with a High Fat Diet. Journal of Alzheimer's Disease, 2018, 66, 1175-1191.	2.6	10
22	Gradual Disturbances of the Amplitude of Low-Frequency Fluctuations (ALFF) and Fractional ALFF in Alzheimer Spectrum. Frontiers in Neuroscience, 2018, 12, 975.	2.8	135
23	Investigation of the neuroprotective effects of crocin via antioxidant activities in HT22 cells and in mice with Alzheimer's disease. International Journal of Molecular Medicine, 2019, 43, 956-966.	4.0	48
24	Advances in Resting State Neuroimaging of Mild Cognitive Impairment. Frontiers in Psychiatry, 2018, 9, 671.	2.6	14
25	The Early Events That Initiate β-Amyloid Aggregation in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 359.	3.4	85
26	The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain, 2018, 141, 1917-1933.	7.6	1,008
27	Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration. Cell, 2018, 173, 1073-1081.	28.9	765
28	Structure-activity relationships of β-hairpin mimics as modulators of amyloid β-peptide aggregation. European Journal of Medicinal Chemistry, 2018, 154, 280-293.	5.5	15
29	Amyloid-β/Drug Interactions from Computer Simulations and Cell-Based Assays. Journal of Alzheimer's Disease, 2018, 64, S659-S672.	2.6	5
30	Impaired <scp>AMPA</scp> signaling and cytoskeletal alterations induce early synaptic dysfunction in a mouse model of Alzheimer's disease. Aging Cell, 2018, 17, e12791.	6.7	58
31	Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease?. Expert Opinion on Therapeutic Targets, 2018, 22, 587-598.	3.4	27
32	A simple approach to quantitative determination of soluble amyloid-β peptides using a ratiometric fluorescence probe. Biosensors and Bioelectronics, 2019, 142, 111518.	10.1	19
33			
	Short amylin receptor antagonist peptides improve memory deficits in Alzheimer's disease mouse model. Scientific Reports, 2019, 9, 10942.	3.3	25
35		3.3 0.8	25 0
35 36	model. Scientific Reports, 2019, 9, 10942.		

#	Article	IF	CITATIONS
38	Brain Structural Correlates of Odor Identification in Mild Cognitive Impairment and Alzheimer's Disease Revealed by Magnetic Resonance Imaging and a Chinese Olfactory Identification Test. Frontiers in Neuroscience, 2019, 13, 842.	2.8	20
39	A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials. Alzheimer's and Dementia, 2019, 15, 1448-1457.	0.8	7
40	Protective roles of isoastilbin against Alzheimer's disease via Nrf2‑mediated antioxidation and anti‑apoptosis. International Journal of Molecular Medicine, 2019, 43, 1406-1416.	4.0	18
41	Seeding and Cross-Seeding Aggregations of Aβ ₄₀ and Its N-Terminal-Truncated Peptide Aβ _{11–40} . Langmuir, 2019, 35, 2821-2831.	3.5	13
42	The Potential Role of Dysregulated miRNAs in Alzheimer's Disease Pathogenesis and Progression. Journal of Alzheimer's Disease, 2019, 67, 1123-1145.	2.6	13
43	Computational design and evaluation of βâ€sheet breaker peptides for destabilizing Alzheimer's amyloidâ€ Î ² ₄₂ protofibrils. Journal of Cellular Biochemistry, 2019, 120, 17935-17950.	2.6	16
44	Plasma MicroRNAs Are Altered Early and Consistently in a Mouse Model of Tauopathy. Neuroscience, 2019, 411, 164-176.	2.3	4
46	Age at onset in genetic prion disease and the design of preventive clinical trials. Neurology, 2019, 93, e125-e134.	1.1	73
47	Overview of novel multifunctional agents based on conjugates of γ-carbolines, carbazoles, tetrahydrocarbazoles, phenothiazines, and aminoadamantanes for treatment of Alzheimer's disease. Chemico-Biological Interactions, 2019, 308, 224-234.	4.0	36
48	Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimer's Research and Therapy, 2019, 11, 27.	6.2	82
49	Why Amyloid Is Still a Target for Alzheimer Disease Clinical Trials. Journal of the American Geriatrics Society, 2019, 67, 845-847.	2.6	4
50	Early-Stage Identification and Pathological Development of Alzheimer's Disease Using Multimodal MRI. Journal of Alzheimer's Disease, 2019, 68, 1013-1027.	2.6	41
51	Design and sample size considerations for Alzheimer's disease prevention trials using multistate models. Clinical Trials, 2019, 16, 111-119.	1.6	15
52	Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7793-7798.	7.1	41
53	Impaired Spatial Reorientation in the 3xTg-AD Mouse Model of Alzheimer's Disease. Scientific Reports, 2019, 9, 1311.	3.3	24
54	GABAâ€containing compound gammapyrone protects against brain impairments in Alzheimer's disease model male rats and prevents mitochondrial dysfunction in cell culture. Journal of Neuroscience Research, 2019, 97, 708-726.	2.9	55
55	Multi-angles of smoking and mild cognitive impairment: is the association mediated by sleep duration?. Neurological Sciences, 2019, 40, 1019-1027.	1.9	10
56	Predictive Value of Routine Peripheral Blood Biomarkers in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2019, 11, 332.	3.4	46

#	Article	IF	CITATIONS
57	Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer's disease. Expert Opinion on Investigational Drugs, 2019, 28, 93-97.	4.1	5
58	Microglia metabolism in health and disease. Neurochemistry International, 2019, 130, 104331.	3.8	56
59	On the role of synthesized hydroxylated chalcones as dual functional amyloid-β aggregation and ferroptosis inhibitors for potential treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2019, 166, 11-21.	5.5	74
60	bioNMR-based identification of natural anti-Aβ compounds in Peucedanum ostruthium. Bioorganic Chemistry, 2019, 83, 76-86.	4.1	26
61	Reduced brain amyloid burden in elderly patients with narcolepsy type 1. Annals of Neurology, 2019, 85, 74-83.	5.3	18
62	Evaluating the Benefits of the TimeSlips Creative Storytelling Program for Persons With Varying Degrees of Dementia Severity. American Journal of Alzheimer's Disease and Other Dementias, 2019, 34, 163-170.	1.9	19
63	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIHâ€EXAMINER as a potential clinical trial endpoint. Alzheimer's and Dementia, 2020, 16, 11-21.	0.8	32
64	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 37-48.	0.8	38
65	The rare and the common: scale and the genetic imaginary in Alzheimer's disease drug development. New Genetics and Society, 2020, 39, 101-126.	1.2	8
66	Frequency-dependent changes in fractional amplitude of low-frequency oscillations in Alzheimer's disease: a resting-state fMRI study. Brain Imaging and Behavior, 2020, 14, 2187-2201.	2.1	52
67	Realâ€Time BODIPYâ€Binding Assay To Screen Inhibitors of the Early Oligomerization Process of Aβ1–42 Peptide. ChemBioChem, 2020, 21, 1129-1135.	2.6	17
68	Strengthened theta-burst transcranial magnetic stimulation as an adjunctive treatment for Alzheimer's disease: An open-label pilot study. Brain Stimulation, 2020, 13, 484-486.	1.6	20
69	Epigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APPswe/PS1dE9 Mice. Molecular Neurobiology, 2020, 57, 1814-1827.	4.0	51
70	Notopterygium incisum extract (NRE) rescues cognitive deficits in APP/PS1 Alzhneimer's disease mice by attenuating amyloid-beta, tau, and neuroinflammation pathology. Journal of Ethnopharmacology, 2020, 249, 112433.	4.1	19
71	Dampened Slow Oscillation Connectivity Anticipates Amyloid Deposition in the PS2APP Mouse Model of Alzheimer's Disease. Cells, 2020, 9, 54.	4.1	17
72	14,15-Epoxyeicosatrienoic Acid Alleviates Pathology in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2020, 40, 8188-8203.	3.6	25
73	Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life. Nature Neuroscience, 2020, 23, 1580-1588.	14.8	53
74	Microglia: Agents of the CNS Pro-Inflammatory Response. Cells, 2020, 9, 1717.	4.1	174

#	Article	IF	CITATIONS
75	Lower brain-derived neurotrophic factor levels are associated with age-related memory impairment in community-dwelling older adults: the Sefuri study. Scientific Reports, 2020, 10, 16442.	3.3	33
76	The efficacy and safety of hachimijiogan for mild Alzheimer disease in an exploratory, open standard treatment controlled, randomized allocation, multicenter trial. Medicine (United States), 2020, 99, e22370.	1.0	3
77	Impact of Mutations on the Conformational Transition from α-Helix to β-Sheet Structures in Arctic-Type Al² ₄₀ : Insights from Molecular Dynamics Simulations. ACS Omega, 2020, 5, 23219-23228.	3.5	6
78	Potential human transmission of amyloid β pathology: surveillance and risks. Lancet Neurology, The, 2020, 19, 872-878.	10.2	46
79	Deciphering inhibitory activity of flavonoids against tau protein kinases: a coupled molecular docking and quantum chemical study. Journal of Biomolecular Structure and Dynamics, 2022, 40, 411-424.	3.5	12
80	Pharmacological Strategies to Improve Dendritic Spines in Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 82, S91-S107.	2.6	13
81	Astaxanthin Ameliorated Parvalbumin-Positive Neuron Deficits and Alzheimer's Disease-Related Pathological Progression in the Hippocampus of AppNL-G-F/NL-G-F Mice. Frontiers in Pharmacology, 2020, 11, 307.	3.5	27
82	Dynamic network connectivity predicts subjective cognitive decline: the Sino-Longitudinal Cognitive impairment and dementia study. Brain Imaging and Behavior, 2020, 14, 2692-2707.	2.1	16
83	The human brain NGF metabolic pathway is impaired in the pre-clinical and clinical continuum of Alzheimers disease. Molecular Psychiatry, 2021, 26, 6023-6037.	7.9	40
84	<p>Effect of the Casein-Derived Peptide Met-Lys-Pro on Cognitive Function in Community-Dwelling Adults Without Dementia: A Randomized, Double-Blind, Placebo-Controlled Trial</p> . Clinical Interventions in Aging, 2020, Volume 15, 743-754.	2.9	9
85	Impaired Hippocampal-Cortical Interactions during Sleep in a Mouse Model of Alzheimer's Disease. Current Biology, 2020, 30, 2588-2601.e5.	3.9	32
86	A Novel Compound YS-5-23 Exhibits Neuroprotective Effect by Reducing β-Site Amyloid Precursor Protein Cleaving Enzyme 1's Expression and H2O2-Induced Cytotoxicity in SH-SY5Y Cells. Neurochemical Research, 2020, 45, 2113-2127.	3.3	2
87	Towards a treatment for genetic prion disease: trials and biomarkers. Lancet Neurology, The, 2020, 19, 361-368.	10.2	60
88	Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer's disease. Translational Psychiatry, 2020, 10, 47.	4.8	44
89	Effect of Piedmont mutation (L34V) on the structure, dynamics, and aggregation of Alzheimer's Aβ40 peptide. Journal of Molecular Graphics and Modelling, 2020, 97, 107571.	2.4	8
90	Is Sleep Disruption a Cause or Consequence of Alzheimer's Disease? Reviewing Its Possible Role as a Biomarker. International Journal of Molecular Sciences, 2020, 21, 1168.	4.1	39
91	Circulating Exosomal miRNA as Diagnostic Biomarkers of Neurodegenerative Diseases. Frontiers in Molecular Neuroscience, 2020, 13, 53.	2.9	90
92	Pharmaceutical applications of organofluorine compounds. , 2020, , 133-214.		0

#	Article	IF	CITATIONS
93	Circulating MicroRNAs as Diagnostic Biomarkers for Motor Neuron Disease. Frontiers in Neuroscience, 2020, 14, 354.	2.8	8
94	Biological sex and DNA repair deficiency drive Alzheimer's disease via systemic metabolic remodeling and brain mitochondrial dysfunction. Acta Neuropathologica, 2020, 140, 25-47.	7.7	45
95	Analysis of the Human Plasma Proteome Using Multiâ€Nanoparticle Protein Corona for Detection of Alzheimer's Disease. Advanced Healthcare Materials, 2021, 10, e2000948.	7.6	19
96	Usnic acid enantiomers restore cognitive deficits and neurochemical alterations induced by Aβ1–42 in mice. Behavioural Brain Research, 2021, 397, 112945.	2.2	12
97	NMR-based Lavado cocoa chemical characterization and comparison with fermented cocoa varieties: Insights on cocoa's anti-amyloidogenic activity. Food Chemistry, 2021, 341, 128249.	8.2	15
98	Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study. Alzheimer's and Dementia, 2021, 17, 605-617.	0.8	17
99	The NGF Metabolic Pathway: New Opportunities for Biomarker Research and Drug Target Discovery. Advances in Experimental Medicine and Biology, 2021, 1331, 31-48.	1.6	2
100	Fluoxetine Promotes Hippocampal Oligodendrocyte Maturation and Delays Learning and Memory Decline in APP/PS1 Mice. Frontiers in Aging Neuroscience, 2020, 12, 627362.	3.4	13
102	βâ€sheet breakers with consecutive phenylalanines: Insights into mechanism of dissolution of βâ€amyloid fibrils. Proteins: Structure, Function and Bioinformatics, 2021, 89, 762-780.	2.6	4
103	Effect of memantine, an anti-Alzheimer's drug, on rodent microglial cells in vitro. Scientific Reports, 2021, 11, 6151.	3.3	5
104	Early detection of amyloid load using 18F-florbetaben PET. Alzheimer's Research and Therapy, 2021, 13, 67.	6.2	26
105	Early intervention attenuates synaptic plasticity impairment and neuroinflammation in 5xFAD mice. Journal of Psychiatric Research, 2021, 136, 204-216.	3.1	18
106	Alzheimer's Disease—Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran. International Journal of Molecular Sciences, 2021, 22, 4805.	4.1	13
107	An Effective Brain Imaging Biomarker for AD and aMCI: ALFF in Slow-5 Frequency Band. Current Alzheimer Research, 2021, 18, 45-55.	1.4	14
108	Recent Progress in the Drug Development for the Treatment of Alzheimer's Disease Especially on Inhibition of Amyloid-peptide Aggregation. Mini-Reviews in Medicinal Chemistry, 2021, 21, 969-990.	2.4	6
109	Tau Pathology Profile Across a Parietal-Hippocampal Brain Network Is Associated With Spatial Reorientation Learning and Memory Performance in the 3xTg-AD Mouse. Frontiers in Aging, 2021, 2, .	2.6	5
110	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nature Medicine, 2021, 27, 1187-1196.	30.7	182
111	Design, synthesis, and biological evaluation of diosgenin-indole derivatives as dual-functional agents for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2021, 219, 113426.	5.5	20

#	Article	IF	CITATIONS
112	Methodological Issues in Randomized Clinical Trials for Prodromal Alzheimer's and Parkinson's Disease. Frontiers in Neurology, 2021, 12, 694329.	2.4	8
113	Connectome-based model predicts episodic memory performance in individuals with subjective cognitive decline and amnestic mild cognitive impairment. Behavioural Brain Research, 2021, 411, 113387.	2.2	9
114	An early proinflammatory transcriptional response to tau pathology is ageâ€specific and foreshadows reduced tau burden. Brain Pathology, 2022, 32, e13018.	4.1	7
115	Improved modeling of human AD with an automated culturing platform for iPSC neurons, astrocytes and microglia. Nature Communications, 2021, 12, 5220.	12.8	38
116	1H-1,2,3-triazole grafted tacrine-chalcone conjugates as potential cholinesterase inhibitors with the evaluation of their behavioral tests and oxidative stress in mice brain cells. Bioorganic Chemistry, 2021, 114, 105053.	4.1	16
117	Complex interactions underlie racial disparity in the risk of developing Alzheimer's disease dementia. Alzheimer's and Dementia, 2020, 16, 589-597.	0.8	25
118	A Perspective on Multi-target Drugs for Alzheimer's Disease. Trends in Pharmacological Sciences, 2020, 41, 434-445.	8.7	148
120	Current Trends in the Development of Drugs for the Treatment of Alzheimer's Disease and their Clinical Trials. Biomedical Chemistry Research and Methods, 2018, 1, e00015.	0.4	7
121	Potential Use of Nanomedicine for the Anti-inflammatory Treatment of Neurodegenerative Diseases. Current Pharmaceutical Design, 2018, 24, 1589-1616.	1.9	21
122	A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer's Disease. Current Pharmaceutical Design, 2020, 26, 1286-1299.	1.9	12
123	Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease. Dialogues in Clinical Neuroscience, 2019, 21, 177-191.	3.7	17
124	Potential preventive disease-modifying pharmacological strategies to delay late onset Alzheimer's disease. Neural Regeneration Research, 2019, 14, 1721.	3.0	2
125	Enhanced Expression of microRNA-1273g-3p Contributes to Alzheimer's Disease Pathogenesis by Regulating the Expression of Mitochondrial Genes. Cells, 2021, 10, 2697.	4.1	10
128	Functional characterization of multifunctional ligands targeting acetylcholinesterase and alpha 7 nicotinic acetylcholine receptor. Biochemical Pharmacology, 2020, 177, 114010.	4.4	6
129	Application for Decision-Making on Mild Cognitive Impairments. Engineering Proceedings, 2021, 7, 55.	0.4	0
130	Cerebrospinal fluid and blood biomarkers in the diagnostic assays of Alzheimer's disease. Journal of Innovative Optical Health Sciences, 2022, 15, .	1.0	9
131	Promising molecular targets for pharmacological therapy of neurodegenerative pathologies. Acta Naturae, 2020, 12, 60-80.	1.7	3
132	Accelerated intermittent theta-burst stimulation broadly ameliorates symptoms and cognition in Alzheimer's disease: A randomized controlled trial. Brain Stimulation, 2022, 15, 35-45.	1.6	28

#	Article	IF	CITATIONS
133	Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay. Journal of Nanobiotechnology, 2021, 19, 366.	9.1	14
134	Essential Oils from Spices Inhibit Cholinesterase Activity and Improve Behavioral Disorder in AlCl3 Induced Dementia. Chemistry and Biodiversity, 2021, , e2100443.	2.1	10
135	Cerebral Phospho-Tau Acts Synergistically with Soluble Al̂ ² 42 Leading to Mild Cognitive Impairment in AAV-AD Rats. journal of prevention of Alzheimer's disease, The, 0, , 1.	2.7	4
136	Animal models in the study of Alzheimer's disease and Parkinson's disease: A historical perspective. Animal Models and Experimental Medicine, 2022, 5, 27-37.	3.3	10
137	Abnormal characterization of dynamic functional connectivity in Alzheimer's disease. Neural Regeneration Research, 2022, 17, 2014.	3.0	29
138	Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 2022, 18, 2687-2698.	0.8	13
139	Conjugates of Tacrine with Salicylamide as Promising Multitarget Agents for Alzheimer's Disease. ChemMedChem, 2022, 17, e202200080.	3.2	11
140	Progress and Development of Carbazole Scaffold Based as Potential Anti- Alzheimer Agents Using MTDL Approach. Letters in Drug Design and Discovery, 2022, 19, 1049-1067.	0.7	3
141	Targeting brain Renin-Angiotensin System for the prevention and treatment of Alzheimer's disease: Past, present and future. Ageing Research Reviews, 2022, 77, 101612.	10.9	26
142	The Nerve Growth Factor Metabolic Pathway Dysregulation as Cause of Alzheimer's Cholinergic Atrophy. Cells, 2022, 11, 16.	4.1	17
144	Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers. Neurotherapeutics, 2022, 19, 209-227.	4.4	36
145	The potential of polygenic scores to improve cost and efficiency of clinical trials. Nature Communications, 2022, 13, .	12.8	19
146	Synthesis and preliminary biological evaluation of new phthalazinone derivatives with PARP-1 and cholinesterase inhibitory activities. Letters in Drug Design and Discovery, 2022, 19, .	0.7	0
148	DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's Disease. Current Medicinal Chemistry, 2023, 30, 669-688.	2.4	8
149	NMR-Driven Identification of Cinnamon Bud and Bark Components With Anti-Aβ Activity. Frontiers in Chemistry, 0, 10, .	3.6	6
150	Textural features reflecting local activity of the hippocampus improve the diagnosis of Alzheimer's disease and amnestic mild cognitive impairment: A radiomics study based on functional magnetic resonance imaging. Frontiers in Neuroscience, 0, 16, .	2.8	6
151	Sleep duration and biomarkers of inflammation in African American and white participants with a parental history of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	3.7	4
152	Dissecting the Inhibitory Mechanism of the αB-Crystallin Domain against Aβ ₄₂ Aggregation and Its Effect on Aβ ₄₂ Protofibrils: A Molecular Dynamics Simulation Study. ACS Chemical Neuroscience, 2022, 13, 2842-2851.	3.5	3

#	Article	IF	CITATIONS
153	Anticholinesterase Compounds from Endemic <i>Prangos uechtritzii</i> . Chemistry and Biodiversity, 2022, 19, .	2.1	2
154	Photobiomodulation and visual stimulation against cognitive decline and Alzheimer's disease pathology: A systematic review. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	3.7	5
155	Disease stages and therapeutic hypotheses in two decades of neurodegenerative disease clinical trials. Scientific Reports, 2022, 12, .	3.3	11
156	Association of lower liver function with cognitive impairment in the Shenzhen ageing-related disorder cohort in China. Frontiers in Aging Neuroscience, 0, 14, .	3.4	2
157	An exploratory, open-label, randomized, multicenter trial of hachimijiogan for mild Alzheimer's disease. Frontiers in Pharmacology, 0, 13, .	3.5	1
158	Identification of a Hydroxygallic Acid Derivative, Zingibroside R1 and a Sterol Lipid as Potential Active Ingredients of Cuscuta chinensis Extract That Has Neuroprotective and Antioxidant Effects in Aged Caenorhabditis elegans. Nutrients, 2022, 14, 4199.	4.1	4
159	Alzheimer's Disease Prevention through Natural Compounds: Cell-Free <i>, In Vitro</i> , and <i>In Vivo</i> Dissection of Hop (<i>Humulus lupulus</i> L.) Multitarget Activity. ACS Chemical Neuroscience, 2022, 13, 3152-3167.	3.5	4
160	Unravelling the relationship between amyloid accumulation and brain network function in normal aging and very mild cognitive decline: a longitudinal analysis. Brain Communications, 2022, 4, .	3.3	3
161	HSI-LFS-BERT: Novel Hybrid Swarm Intelligence Based Linguistics Feature Selection and Computational Intelligent Model for Alzheimer's Prediction Using Audio Transcript. IEEE Access, 2022, 10, 126990-127004.	4.2	4
162	Experimental evidence for temporal uncoupling of brain $\hat{A^2}$ deposition and neurodegenerative sequelae. Nature Communications, 2022, 13, .	12.8	6
163	Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer's disease pathology. Nature Aging, 2022, 2, 1138-1144.	11.6	19
164	Lateral flow assays for detection of disease biomarkers. Journal of Pharmaceutical and Biomedical Analysis, 2023, 225, 115206.	2.8	9
165	Current Pharmacotherapy and Multi-Target Approaches for Alzheimer's Disease. Pharmaceuticals, 2022, 15, 1560.	3.8	18
166	Methods for the isolation and analysis of $A\hat{l}^2$ from postmortem brain. Frontiers in Neuroscience, 0, 17, .	2.8	Ο
167	Animal models in Alzheimer's disease: Biological plausibility and mood disorders. Neurology Perspectives, 2023, 3, 100110.	0.5	1
168	Conjugates of Tacrine and Salicylic Acid Derivatives as New Promising Multitarget Agents for Alzheimer's Disease. International Journal of Molecular Sciences, 2023, 24, 2285.	4.1	7
169	Multifactorial glial responses and their contributions to Alzheimer's disease continuum. Clinical and Experimental Neuroimmunology, 2023, 14, 82-91.	1.0	1
170	Ultrasensitive and point-of-care detection of plasma phosphorylated tau in Alzheimer's disease using colorimetric and surface-enhanced Raman scattering dual-readout lateral flow assay. Nano Research, 2023, 16, 7459-7469.	10.4	9

#	Article	IF	CITATIONS
171	Effect of Ovocystatin on Amyloid β 1-42 Aggregation—In Vitro Studies. International Journal of Molecular Sciences, 2023, 24, 5433.	4.1	2
173	Volume changes of hippocampal and amygdala subfields in patients with mild cognitive impairment and Alzheimer's disease. Acta Neurologica Belgica, 2023, 123, 1381-1393.	1.1	3
174	Correlation between ankleâ€brachial index and subtle cognitive decline. Brain and Behavior, 2023, 13, .	2.2	0
175	Salivary 3â€methoxyâ€4â€hydroxyphenylglycol and <scp>MRI</scp> â€based volume change of the precuneus in communityâ€dwelling elderly people. Psychogeriatrics, 0, , .	1.2	0
176	Direct Enhancement Effect of Hippocampal Cholinergic Neurostimulating Peptide on Cholinergic Activity in the Hippocampus. International Journal of Molecular Sciences, 2023, 24, 8916.	4.1	0
177	An activatable small-molecule fluorogenic probe for detection and quantification of beta-amyloid aggregates. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2023, 303, 123145.	3.9	0
178	Increased microglia activation in late non entral nervous system cancer survivors links to chronic systemic symptomatology. Human Brain Mapping, 0, , .	3.6	0
179	A holo-spectral EEG analysis provides an early detection of cognitive decline and predicts the progression to Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 15, .	3.4	1
180	Effectiveness of Tai Chi on cognitive function among older adults with mild cognitive impairment: a systematic review and meta-analysis of randomized controlled trials. Aging and Mental Health, 2024, 28, 285-293.	2.8	0
182	Alzheimer's disease: From immunotherapy to immunoprevention. Cell, 2023, 186, 4260-4270.	28.9	17
183	Molecular insights into the structure destabilization effects of ECG and EC on the AÎ ² protofilament: An all-atom molecular dynamics simulation study. International Journal of Biological Macromolecules, 2023, 253, 127002.	7.5	0
184	[18F]-FDG uptake in brain slices prepared from an aged mouse model of Alzheimer's disease using a dynamic autoradiography technique. Annals of Nuclear Medicine, 2024, 38, 120-130.	2.2	0
187	Natural molecules in neuroprotection and neurotoxicity in neurodegenerative diseases. , 2024, , 3-28.		0
188	Conjugates of tacrine with aminomethylidene derivatives of ethyl acetoacetate as promising agents for the treatment of Alzheimer's disease. Russian Chemical Bulletin, 2023, 72, 2994-3004.	1.5	0
189	TrkB phosphorylation in serum extracellular vesicles correlates with cognitive function enhanced by ergothioneine in humans. Npj Science of Food, 2024, 8, .	5.5	1